Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~Male and non-pregnant females aged ≥ 18 to ≤ 60 years on the day of inclusion Able to comprehend and give informed consent Able to attend all scheduled visits and to comply with all trial procedures Subject in good health, based on medical history and physical examination~Exclusion Criteria:~1. Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be post- menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination).~2. Participation in the 4 weeks preceding the first trial vaccination, or planned participation during the present trial period, in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.~3. Previous history of receiving the rabies vaccine.~4. Previous history of receiving rabies immune globulin.~5. Any major psychiatric disorder, such as severe depression, severe anxiety disorder, psychosis, schizophrenia, other major psychiatric disorders, or seizures. History of mild depression or anxiety disorder that is well controlled is not an exclusion criteria.~6. Any history of cardiac arrhythmias, such as: Bradycardia, tachycardia, heart block, SVT, PAC, VF, VT, or any other conduction abnormalities.~7. Use of any immunosuppressive drug , including topical steroids of potency groups I, II or III within 30 days of the study period.~8. Any immunosuppressive disorder, such as HIV, common variable, active cancers or chemotherapy.~9. History of renal insufficiency or requiring dialysis.~10. Any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.~11. Identified as an employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employee or the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Rabies vaccine IM 3 dose (Type: ACTIVE_COMPARATOR): Intramuscular injection: 1mL at 0, 7 and 21 days. An additional 1 mL intramuscular dose at day 365
- Rabies vaccine ID 3 dose (Type: EXPERIMENTAL): Intradermal injection: 0.1mL at 0, 7 and 21 days. A single intramuscular 1 mL dose at day 365
- Rabies vaccine IM 2 dose (Type: EXPERIMENTAL): Intramuscular injection: 1mL at 0, 7 days. An additional 1 mL intramuscular dose at day 365
- Rabies vaccine ID 2 dose (Type: EXPERIMENTAL): Intradermal injection: 0.1mL at 0, 7 days. A single intramuscular 1 mL dose at day 365
- Placebo IM 1 dose (Type: PLACEBO_COMPARATOR): Albumin and saline comparator, Intramuscular injection: 1mL
- Placebo ID 1 dose (Type: PLACEBO_COMPARATOR): Albumin and saline comparator, Intradermal injection: 0.1mL

Based on this trial design, predict the completion outcome and termination type (if applicable).